Quantum Biopharma (NASDAQ: QNTM) Enlists Thermo Fisher's Clinical Research Business To Launch Phase 2 Lucid-MS Trial

New agreement moves innovative Lucid-MS treatment from planning into execution. Proprietary platform is designed around a novel neuroprotective approach that targets demyelination rather than solely modulating the immune system. Thermo Fisher's clinical research business is a leading global contract research organization, with impressive expertise in central nervous system and MS studies.

Most multiple sclerosis (“MS”) drugs work by quieting the immune system. A new partnership shines the spotlight on a different approach - protecting the nerve's own insulation - and sets up that treatment for a rigorous clinical test. Quantum BioPharma (NASDAQ: QNTM), a biopharmaceutical company developing therapies for neurodegenerative and metabolic disorders, has signed a Study Start-Up Agreement with the clinical research business of Thermo Fisher Scientific. The contract covers implementation of the phase 2 trial of Lucid-MS, Quantum's lead drug candidate for MS.

Read More>>

NOTE TO INVESTORS: IBN is a multifaceted financial news, content creation and publishing company utilized by both public and private companies to optimize investor awareness and recognition. For more information, please visit

Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published:

The latest news and updates relating to QNTM are available in the company's newsroom at

Corporate Communications

IBN
Austin, Texas

512.354.7000 Office
[email protected]

IBN

[email protected]

MENAFN07102026005728012573ID1111776092